Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes, which are a series of four Phase II clinical trials.

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...